Pre-clinical models have shown that an ADC combining a MUC-1 targeting antibody with the staphylococcal enterotoxin A (SEA) has activity against cholangiocarcinoma cell lines and that this activity can be augmented by LAK cells. The gene discussed is MUC1; the disease is cholangiocarcinoma.